- Home
- CELH vs QGEN Comparison
CELH vs QGEN Comparison
Compare CELH & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | QGEN |
|---|---|---|
| Founded | 2004 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.7B |
| IPO Year | 2008 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CELH | QGEN |
|---|---|---|
| Price | $29.09 | $42.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $64.81 | $45.76 |
| AVG Volume (30 Days) | ★ 11.5M | 2.4M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $1,318,014,000.00 | N/A |
| Revenue This Year | $37.04 | $8.18 |
| Revenue Next Year | $9.89 | $5.71 |
| P/E Ratio | $61.28 | ★ $24.01 |
| Revenue Growth | ★ 101.65 | N/A |
| 52 Week Low | $23.56 | $32.53 |
| 52 Week High | $66.74 | $57.82 |
Technical Indicators
Market Signals| Indicator | CELH | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 58.85 |
| Support Level | $27.39 | $42.82 |
| Resistance Level | $30.93 | $44.03 |
| Average True Range (ATR) | 1.58 | 0.87 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 71.18 | 55.93 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It focuses on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).